Understanding how gut bacteria and immune cells affect lung cancer treatment response
Intratumoral microbiota and immune predictors of response to immunotherapy in lung cancer
This study is looking at how the bacteria in lung tumors and the immune cells around them can help predict how well patients with advanced lung cancer will respond to immunotherapy, so we can better understand who might benefit from this treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10981747 on NIH RePORTER |
What this research studies
This research investigates the relationship between the bacteria present in lung tumors and the immune cells that infiltrate these tumors to predict how well patients with advanced lung cancer will respond to immunotherapy. By analyzing tumor samples from patients before they receive treatment, the study aims to identify specific biomarkers that can indicate whether a patient is likely to benefit from immune checkpoint inhibitors. The research will involve a large cohort of patients and utilize advanced analytical techniques to create a predictive model for treatment response.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced Non-Small Cell Lung Cancer who are about to start immunotherapy.
Not a fit: Patients with early-stage lung cancer or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for lung cancer patients, improving their chances of responding to immunotherapy.
How similar studies have performed: Previous research has shown promising results in linking microbiota and immune responses to treatment outcomes in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Liu, Yanhong — Baylor College of Medicine
- Study coordinator: Liu, Yanhong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.